Biotech Values

[DewDiligence]

VXRT +135% on phase-2 flu-challenge study for oral vaccine:

https://www.businesswire.com/news/home/20181004005175/en

…[Our vaccine provided] a robust 39% reduction in illness versus placebo overall. In contrast, Fluzone, the market-leading injectable quadrivalent influenza vaccine, only provided a 27% reduction in illness versus placebo…

I own VXRT in the SI charity portfolio.

p.s. Today’s PR is presumably the reason for the suspicious bump in the share price two weeks ago (#msg-143683222).

p.p.s. A capital raise seems pretty likely insofar as VXRT’s cash balance at 6/30/18 was only $23.9M (#msg-142795582).